THE NUCALA PATIENT
If you have patients like these, NUCALA may help
Patients 6 years and older with severe asthma and:
*For patients 6-11 taking medium- to high-dose ICS + additional controller. See Pediatric Use.
†Exacerbations defined as worsening of asthma requiring OCS and/or hospitalization and/or ED visits; for patients ≥12 years on maintenance OCS, exacerbations defined as at least doubling the existing maintenance dose for ≥3 days.
FREQUENT EXACERBATIONS

37-year-old male
FROM AN EXPERT
See how NUCALA can help in this patient type.
Medical History and Report
- Asthma diagnosis at age 28
- Atopic status: positive (prior SCIT)
- 3 exacerbations in the past year, 2 requiring hospitalization, no intubations
- Currently taking high-dose ICS/LABA (9 years) + LAMA (5 years) + LTRA (4 years), nasal corticosteroid spray, albuterol as needed
- Allergic rhinitis, chronic sinus congestion
- Persistent dyspnea, intermittent wheezing, symptoms frequently disrupt sleep, frequent use of rescue inhaler
- Symptoms limit exercise and social activity
Spirometry
- FEV1: 64% predicted
- FEV1/FVC ratio: 0.71
Laboratory Assessment
- CBC with differential
- Eosinophil count: 428 cells/µL
- Total IgE: 140 kU/L
CBC=complete blood count; FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; ICS=inhaled corticosteroid; IgE=immunoglobulin E; LABA=long-acting beta2-adrenergic agonist; LAMA=long-acting muscarinic antagonist; LTRA=leukotriene receptor antagonist; SCIT=subcutaneous immunotherapy.
FREQUENT EXACERBATIONS AND COMORBID NASAL POLYPS

43-year-old male
FROM AN EXPERT
See how NUCALA can help in this patient type.
Medical History and Report
- Asthma diagnosis at age 18
- Presence of nasal polyps
- History of SCIT
- 2 exacerbations in the past year, including a hospitalization
- Currently taking high-dose ICS/LABA (13 years) + LTRA (6 years), nasal corticosteroid spray, albuterol as needed
- Persistent dyspnea, disrupts sleep
Spirometry
- FEV1: 66% predicted
- FEV1/FVC ratio: 0.69
Laboratory Assessment
- CBC with differential
- Eosinophil count: 324 cells/µL
- Total IgE: 352 kU/L
OCS DEPENDENT

47-year-old female
FROM AN EXPERT
See how NUCALA can help in this patient type.
Medical History and Report
- Asthma diagnosis at age 29
- 2 exacerbations in previous 12 months (outpatient, treated with high-dose OCS, 1 hospitalization in the past year)
- Currently taking OCS 12.5 mg (daily, 9 months), high-dose ICS/LABA (13 years) + LTRA (7 years), albuterol as needed
- Persistent symptoms have interfered with work and exercise
- Weight gain of 15 lbs in the last 9 months
Spirometry
- FEV1: 62% predicted
- FEV1/FVC ratio: 0.70
Laboratory Assessment
- CBC with differential
- Eosinophil count: 157 cells/µL
- Total IgE: 114 kU/L
PEDIATRIC

10-year-old male
Medical History and Report
- Asthma diagnosis at age 6
- 2 exacerbations in the past year; 1 hospitalization in the past year
- Currently taking high-dose ICS/LABA (3 years) + LAMA (2 years), nasal corticosteroid spray, albuterol as needed
- Persistent dyspnea, intermittent wheezing, frequent use of rescue inhaler
- Missed school due to asthma symptoms
Spirometry
- FEV1: 64% predicted
- FEV1/FVC ratio: 0.71
Laboratory Assessment
- CBC with differential
- Eosinophil count: 370 cells/µL
- Total IgE: 148 kU/L
How can NUCALA help these patients?
ED=emergency department, ICS=inhaled corticosteroids; OCS=oral corticosteroids.